AXL and cancer: However, the results from a phase 1/2 clinical trial conducted with Enapotamab Vedotin, an anti-AXL antibody coupled with the auristatine E, in non-small cell lung cancer (NSCLC) patients, demonstrated a manageable safety profile, suggesting no critical concerns about AXL off-target effects in cancer patients [43].